06185 康希諾生物
按盘价 
28.450 +0.950 (+3.455%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 资产回报率 (%) | -14.265% | -7.792% | 20.560% | -9.297% | -12.151% |
| 股东资金回报率 (%) | -24.666% | -12.337% | 27.220% | -10.519% | -15.892% |
| 资本运用回报率 (%) | -22.042% | -10.665% | 21.273% | -6.261% | -9.443% |
边际利润分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | -253.785% | -18.099% | 69.817% | 25.561% | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -511.302% | -110.450% | 46.771% | -1990.498% | N/A |
| 税前边际利润率 (%) | -573.287% | -114.835% | 45.045% | -2138.902% | N/A |
| 纯利率 (%) | -429.551% | -88.205% | 44.524% | -2138.902% | N/A |
变现能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流动比率 (X) | 1.999 X | 2.627 X | 3.231 X | 13.130 X | 6.390 X |
| 速动比率 (X) | 1.864 X | 2.397 X | 2.927 X | 12.717 X | 6.259 X |
财务杠杆分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 总负债 / 总资产比率 (%) | 43.261% | 36.824% | 28.013% | 10.036% | 17.595% |
| 总债项 / 总资产比率 (%) | 28.977% | 23.547% | 11.578% | 2.112% | 9.347% |
| 净债项 / 总资产比率 (%) | 7.011% | -6.053% | -34.378% | -63.788% | -1.998% |
| 总债项 / 股东资金比率 (%) | 51.195% | 40.021% | 17.196% | 2.348% | 11.343% |
| 长期债项 / 股东资金比率 (%) | 23.525% | 15.950% | 3.288% | 1.545% | 9.368% |
| 净债项 / 股东资金比率 (%) | 12.387% | -10.287% | -51.057% | -70.904% | -2.424% |
| 净现金 / (债项) ($) | (6.53亿) | 6.94亿 | 40.82亿 | 43.04亿 | 3.57千万 |
| 每股净现金 / (债项) ($) | (2.640) | 2.805 | 16.497 | 17.395 | 0.160 |
| 总债项 / 资本运用比率 (%) | 40.142% | 31.672% | 15.277% | 2.250% | 10.047% |
| 利息盈利率 (X) | N/A | N/A | 95.852 X | N/A | N/A |
营运效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存货周转率日数 (日) | 153.692日 | 232.822日 | 147.113日 | 2470.308日 | -- |
| 应收贸易帐周转率日数 (日) | 789.027日 | 179.380日 | 7.622日 | 425.919日 | N/A |
| 应付贸易帐周转率日数 (日) | 188.796日 | 193.943日 | 38.334日 | 656.858日 | N/A |
| 备注： | 实时报价更新时间为29/11/2024 12:41 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -225,373,000 |
| 增长率 | -73.215% |
| 每股盈利/(亏损) | RMB -0.910 |
| 每股账面资产净值 (¥) | RMB 20.447 |